Logo Image
|Podcasts|January 16, 2012

Podcast: 2012 Retrospective on Separations Technology

Mike Ultee, chief scientific officer of Laureate Biopharmaceutical Services, discusses advances in separations technology, beginning with the 1988 publication of ?Separations Technology Outlook, Part II? by Nancy E. Pfund and Kathleen G. Charles.

Throughout BioPharm International's 25th Anniversary Year, 2012, we will be rewinding to articles published in the journal's first volume to see where and how technologies have changed in the past couple of decades as well as what the industry may look forward to. Here, Mike Ultee, chief scientific officer of Laureate Biopharmaceutical Services and member of BioPharm International’s editorial advisory board, discusses advances in separations technology, beginning with the 1988 publication of “Separations Technology Outlook, Part II” by Nancy E. Pfund and Kathleen G. Charles. (Posted January 2012).

Related to this article

View more
The BioPharm Brief: Survival, Gene Editing, and Skin Cancer
The BioPharm Brief: Survival, Gene Editing, and Skin Cancer
This episode of the BioPharm Brief highlights Roche’s Tam-Peli phase 3 survival data in relapsed small-cell lung cancer, Cellectis’ shift to in vivo gene editing for lipid disorders, and Phio Pharmaceuticals’ FDA briefing package for PH-762 in cutaneous squamous cell carcinoma.
Read more
The BioPharm Brief: Delivery, Priority, and Gene Therapy
The BioPharm Brief: Delivery, Priority, and Gene Therapy
The BioPharm Brief highlights Biora Therapeutics’ first human trial of its BioJet oral delivery system, FDA priority review of Roche’s satralizumab for MOGAD, and Encoded Therapeutics’ $275 million financing for its Dravet syndrome gene therapy ETX101.
Read more